APC: Psychedelic Facilitated Psychotherapy for Addiction-Slides

Slides

Pdf Summary

The document discusses the use of psychedelic-assisted psychotherapy for the treatment of substance use disorders. It begins by providing a disclosure of the author's involvement with MDMA-assisted psychotherapy and the study drugs used. The document emphasizes that psilocybin, one of the psychedelic substances discussed, is currently a Schedule I substance and requires strict oversight for its use. The learning objectives of the curriculum include reviewing the history of psychedelic-assisted psychotherapy, assessing existing literature and ongoing research on its use for substance use disorders, and exploring the training and certification landscape for this type of therapy.<br /><br />The document provides information on the different types of psychedelics, such as psilocybin, LSD, mescaline, and MDMA, and their contexts and classifications. It discusses the pharmacokinetics and pharmacodynamics of psilocybin, including its metabolism, excretion, and effects on serotonin receptors.<br /><br />The document highlights the prevalence of substance use disorders, focusing on alcohol, tobacco, opioid, cocaine, and methamphetamine use disorders. It presents research studies and ongoing clinical trials exploring the use of psychedelic-assisted therapy for these disorders, including their effectiveness in reducing substance use and improving outcomes.<br /><br />The document also addresses potential adverse events associated with psychedelic use and the importance of conducting further research to fully understand the risks and benefits of using psilocybin therapy for substance use disorders.<br /><br />Overall, the document provides an overview of psychedelic-assisted psychotherapy for substance use disorders and highlights the current research and ongoing studies in this field.

Keywords

psychedelic-assisted psychotherapy

substance use disorders

MDMA-assisted psychotherapy

psilocybin

Schedule I substance

pharmacokinetics

pharmacodynamics

prevalence of substance use disorders

adverse events

psilocybin therapy

	The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.		400 Massasoit Avenue Suite 307 East Providence, RI 02914 cmecpd@aaap.org	About Advocacy Membership Fellowship Education and Resources Training Events